In breast cancer this mainly occurs via mutations resulting in overexpression of hormone receptors including the estrogen receptor (ER), androgen receptor (AR), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and their corresponding ligands [20, 56, 57]. This evidence concerns the gene ERBB2 and breast carcinoma.